10x Genomics Inc (TXG) concluded trading on Wednesday at a closing price of $12.00, with 4.13 million shares of worth about $49.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.93% during that period and on February 12, 2025 the price saw a gain of about 1.52%. Currently the company’s common shares owned by public are about 106.98M shares, out of which, 100.20M shares are available for trading.
Stock saw a price change of -18.37% in past 5 days and over the past one month there was a price change of -23.62%. Year-to-date (YTD), TXG shares are showing a performance of -16.43% which decreased to -75.78% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.68 but also hit the highest price of $51.22 during that period. The average intraday trading volume for 10x Genomics Inc shares is 2.04 million. The stock is currently trading -17.32% below its 20-day simple moving average (SMA20), while that difference is down -19.47% for SMA50 and it goes to -36.44% lower than SMA200.
10x Genomics Inc (NASDAQ: TXG) currently have 106.98M outstanding shares and institutions hold larger chunk of about 81.00% of that.
The stock has a current market capitalization of $1.45B and its 3Y-monthly beta is at 1.90. It has posted earnings per share of -$1.53 in the same period. It has Quick Ratio of 4.12 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXG, volatility over the week remained 8.54% while standing at 6.99% over the month.
Stock’s fiscal year EPS is expected to rise by 13.79% while it is estimated to increase by 24.71% in next year. EPS is likely to grow at an annualized rate of 17.40% for next 5-years, compared to annual growth of -13.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on September 03, 2024 offering an Outperform rating for the stock and assigned a target price of $35 to it. Coverage by Jefferies stated 10x Genomics Inc (TXG) stock as a Buy in their note to investors on July 22, 2024, suggesting a price target of $24 for the stock. On July 18, 2024, JP Morgan Downgrade their recommendations, while on July 10, 2024, Deutsche Bank Downgrade their ratings for the stock with a price target of $25. Stock get a Peer perform rating from Wolfe Research on June 27, 2024.
